In a patient with elevated total leukocyte count, marked eosinophilia, hepatosplenomegaly, a hypercellular bone marrow packed with eosinophilic precursors, and elevated serum alkaline phosphatase, what is the most likely diagnosis?

Diagnosis: Primary (Neoplastic) Hypereosinophilic Syndrome or Chronic Eosinophilic Leukemia, NOS

Based on the clinical presentation of elevated total leukocyte count, marked eosinophilia, hepatosplenomegaly, hypercellular bone marrow packed with eosinophilic precursors, and elevated alkaline phosphatase, the most likely diagnosis is a primary (clonal/neoplastic) hypereosinophilic syndrome (HES-N) or chronic eosinophilic leukemia, not otherwise specified (CEL-NOS), pending molecular and cytogenetic confirmation.

Diagnostic Reasoning

Key Clinical Features Supporting Clonal Disease

The constellation of findings strongly suggests a myeloproliferative neoplasm with eosinophilia rather than reactive eosinophilia 1:

• Hepatosplenomegaly: This is a hallmark feature of myeloproliferative variants and primary HES-N, particularly when associated with elevated serum tryptase or vitamin B12 levels 1
• Hypercellular bone marrow with eosinophilic precursors: This morphologic finding is critical—bone marrow morphology showing features resembling myelodysplastic syndromes, myeloproliferative neoplasms, or myelodysplastic/myeloproliferative neoplasms is present in 94% of CEL-NOS cases 2
• Elevated alkaline phosphatase: While not specific, this can indicate bone involvement or hepatic infiltration from the underlying myeloid neoplasm

Immediate Next Steps Required

You must obtain the following tests immediately to establish the definitive diagnosis 1:

1. Molecular screening for tyrosine kinase (TK) fusion gene rearrangements:

   • PDGFRA (most common, especially FIP1L1-PDGFRA)
   • PDGFRB
   • FGFR1
   • JAK2, ABL1, FLT3
   • Use FISH and/or nested RT-PCR 1

2. Conventional cytogenetics: Look for nonspecific abnormalities like trisomy 8 or isochromosome 17 1

3. Peripheral blood blast count: CEL-NOS requires >2% blasts in peripheral blood or >5% in bone marrow (but <20% in both) 1

4. Serum tryptase and vitamin B12 levels: Elevated levels strongly suggest myeloproliferative variant, particularly with PDGFRA rearrangement 1

5. Flow cytometry with T-cell immunophenotyping: To exclude lymphocyte-variant HES (L-HES), which shows aberrant T-cell populations (CD3-, CD4+, CD8- or other abnormal phenotypes) 1

6. Next-generation sequencing (NGS) myeloid mutation panel: If TK fusion genes are negative, this helps distinguish CEL-NOS from reactive eosinophilia 1

Differential Diagnosis Framework

Primary (Clonal) vs Secondary (Reactive) Eosinophilia

The presence of hepatosplenomegaly and hypercellular bone marrow with eosinophilic precursors makes primary HES-N or CEL-NOS far more likely than reactive causes 1. However, you must systematically exclude:

Secondary causes to rule out 1:

• Parasitic infections (especially Strongyloides stercoralis—check travel history, stool ova/parasites, Strongyloides serology)
• Allergic disorders (most common cause of reactive eosinophilia—80% of cases)
• Lymphoid malignancies (Hodgkin lymphoma, T-cell lymphomas—more common than solid tumors)
• Solid tumors (usually only in advanced disease)
• Drug reactions

Specific Diagnostic Categories

If TK fusion genes are positive 1:

• Diagnosis: Myeloid/lymphoid neoplasm with eosinophilia and TK fusion gene
• Most commonly FIP1L1-PDGFRA positive
• Excellent response to imatinib (100 mg daily, can increase to 400 mg if needed)
• This is a curable condition with tyrosine kinase inhibitors

If TK fusion genes are negative but bone marrow shows 1:

• Increased blasts (≥5% to <20%) OR
• Cytogenetic abnormalities (trisomy 8, isochromosome 17) OR
• Morphologic evidence of eosinophilic myeloid neoplasm
• Diagnosis: Chronic eosinophilic leukemia, NOS (CEL-NOS)

If no TK fusion genes, no cytogenetic abnormalities, and no increased blasts 1:

• But hepatosplenomegaly, elevated tryptase, and abnormal bone marrow morphology present
• Diagnosis: Primary (neoplastic) HES (HES-N) or idiopathic HES (diagnosis of exclusion)

Critical Pitfalls to Avoid

1. Do not delay molecular testing: The presence of PDGFRA rearrangement completely changes management and prognosis—these patients respond dramatically to low-dose imatinib 1, 3

2. Do not assume reactive eosinophilia: The combination of hepatosplenomegaly + hypercellular bone marrow + elevated alkaline phosphatase makes clonal disease highly likely 2

3. Do not miss L-HES: This variant (10-20% of HES cases) can evolve to T-cell lymphoma or Sézary syndrome—requires flow cytometry with T-cell immunophenotyping 1

4. Bone marrow morphology is crucial: Abnormal bone marrow features are present in 94% of CEL-NOS cases and only 20% of truly reactive idiopathic HES—this is a strong discriminator 2

5. Elevated alkaline phosphatase requires correlation: While it can indicate bone or liver involvement from the myeloid neoplasm, ensure you're not missing concurrent systemic mastocytosis (which can also present with hepatosplenomegaly, leukocytosis, and elevated alkaline phosphatase) 4

Prognostic Implications

Patients with abnormal bone marrow morphology have significantly shorter survival (48.1 months vs. not reached, P<0.001) compared to those with reactive eosinophilia 2. This finding is independent of other factors and underscores the importance of distinguishing clonal from reactive disease.

The presence of hepatosplenomegaly, elevated tryptase, bone marrow fibrosis, and/or lymphadenopathy after excluding reactive causes strongly indicates primary HES-N 1, which requires aggressive workup and consideration for targeted therapy or clinical trial enrollment.